Wooridul Huebrain Limited (118000.KS)
KRW 298.0
(-1.32%)
KRW 298.0
(-1.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 17.6 Billion KRW | -70.8% |
| 2022 | 60.27 Billion KRW | 5.93% |
| 2021 | 56.9 Billion KRW | -8.47% |
| 2020 | 62.16 Billion KRW | 83.55% |
| 2019 | 33.86 Billion KRW | -21.1% |
| 2018 | 42.92 Billion KRW | 138.07% |
| 2017 | 18.03 Billion KRW | 17.03% |
| 2016 | 15.4 Billion KRW | 50.77% |
| 2015 | 10.21 Billion KRW | -10.02% |
| 2014 | 11.35 Billion KRW | 91.74% |
| 2013 | 5.92 Billion KRW | -25.82% |
| 2012 | 7.98 Billion KRW | -80.78% |
| 2011 | 41.53 Billion KRW | -22.4% |
| 2010 | 53.52 Billion KRW | 161.65% |
| 2009 | 20.45 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.54 Billion KRW | -79.86% |
| 2024 Q2 | 3.72 Billion KRW | 5.19% |
| 2023 Q2 | 46.09 Billion KRW | -6.65% |
| 2023 Q1 | 49.37 Billion KRW | -18.08% |
| 2023 FY | 17.6 Billion KRW | -70.8% |
| 2023 Q3 | 28.52 Billion KRW | -38.11% |
| 2023 Q4 | 17.6 Billion KRW | -38.31% |
| 2022 Q3 | 27.08 Billion KRW | -16.21% |
| 2022 Q1 | 56.77 Billion KRW | -0.22% |
| 2022 FY | 60.27 Billion KRW | 5.93% |
| 2022 Q4 | 60.27 Billion KRW | 122.56% |
| 2022 Q2 | 32.32 Billion KRW | -43.07% |
| 2021 Q1 | 69.98 Billion KRW | 12.58% |
| 2021 Q3 | 59.56 Billion KRW | -13.02% |
| 2021 Q4 | 56.9 Billion KRW | -4.46% |
| 2021 Q2 | 68.47 Billion KRW | -2.16% |
| 2021 FY | 56.9 Billion KRW | -8.47% |
| 2020 Q2 | 27.42 Billion KRW | -0.34% |
| 2020 Q4 | 62.16 Billion KRW | 7.99% |
| 2020 FY | 62.16 Billion KRW | 83.55% |
| 2020 Q1 | 27.52 Billion KRW | -18.75% |
| 2020 Q3 | 57.56 Billion KRW | 109.89% |
| 2019 Q1 | 38.07 Billion KRW | -11.3% |
| 2019 Q2 | 50.71 Billion KRW | 33.18% |
| 2019 FY | 33.86 Billion KRW | -21.1% |
| 2019 Q3 | 55.89 Billion KRW | 10.22% |
| 2019 Q4 | 33.86 Billion KRW | -39.4% |
| 2018 Q4 | 42.92 Billion KRW | 6.17% |
| 2018 Q3 | 40.43 Billion KRW | 193.93% |
| 2018 Q2 | 13.75 Billion KRW | -9.37% |
| 2018 FY | 42.92 Billion KRW | 138.07% |
| 2018 Q1 | 15.17 Billion KRW | -15.83% |
| 2017 Q1 | 15.78 Billion KRW | 2.46% |
| 2017 Q4 | 18.03 Billion KRW | -28.06% |
| 2017 FY | 18.03 Billion KRW | 17.03% |
| 2017 Q2 | 21.54 Billion KRW | 36.48% |
| 2017 Q3 | 25.06 Billion KRW | 16.33% |
| 2016 Q2 | 15.6 Billion KRW | 94.08% |
| 2016 FY | 15.4 Billion KRW | 50.77% |
| 2016 Q4 | 15.4 Billion KRW | 7.54% |
| 2016 Q3 | 14.32 Billion KRW | -8.2% |
| 2016 Q1 | 8.04 Billion KRW | -21.31% |
| 2015 FY | 10.21 Billion KRW | -10.02% |
| 2015 Q3 | 9.98 Billion KRW | 20.34% |
| 2015 Q2 | 8.29 Billion KRW | -32.18% |
| 2015 Q1 | 12.23 Billion KRW | 7.68% |
| 2015 Q4 | 10.21 Billion KRW | 2.39% |
| 2014 Q4 | 11.35 Billion KRW | 17.82% |
| 2014 FY | 11.35 Billion KRW | 91.74% |
| 2014 Q3 | 9.63 Billion KRW | -0.5% |
| 2014 Q2 | 9.68 Billion KRW | 90.52% |
| 2014 Q1 | 5.08 Billion KRW | -14.15% |
| 2013 FY | 5.92 Billion KRW | -25.82% |
| 2013 Q4 | 5.92 Billion KRW | 0.0% |
| 2012 Q2 | 17.82 Billion KRW | -17.74% |
| 2012 Q3 | 17.46 Billion KRW | -1.97% |
| 2012 Q4 | 7.98 Billion KRW | -54.29% |
| 2012 FY | 7.98 Billion KRW | -80.78% |
| 2012 Q1 | 21.66 Billion KRW | -47.84% |
| 2011 Q4 | 41.53 Billion KRW | -39.92% |
| 2011 Q3 | 69.12 Billion KRW | 0.57% |
| 2011 FY | 41.53 Billion KRW | -22.4% |
| 2011 Q1 | 72.14 Billion KRW | 34.79% |
| 2011 Q2 | 68.73 Billion KRW | -4.73% |
| 2010 FY | 53.52 Billion KRW | 161.65% |
| 2010 Q3 | 50.72 Billion KRW | -0.19% |
| 2010 Q1 | 53.4 Billion KRW | 0.0% |
| 2010 Q4 | 53.52 Billion KRW | 5.52% |
| 2010 Q2 | 50.82 Billion KRW | -4.84% |
| 2009 FY | 20.45 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Daewoong Co., Ltd. | 922.47 Billion KRW | 98.092% |
| PharmGen Science, Inc. | 107.7 Billion KRW | 83.659% |